1 to 9 of 15 results

Forest Laboratories announces new appointments to its executive team


New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

GA and PhRMA partner on pilot scheme to enhance patient engagement in three therapy areas


The USA’s Genetic Alliance and the Pharmaceutical Research and Manufacturers of America have announced…

Gastro-intestinalsHealthcareHematologyNorth AmericaPharmaceuticalRespiratory and Pulmonary

Abraaj sells stake in Opalia Pharma to Recordati


The Dubai-based Abraaj Group, an investor operating in global growth markets, has announced its full…

Abraaj GroupDermatologicalsGastro-intestinalsGenericsMergers & AcquisitionsOpalia PharmaRecordatiRespiratory and PulmonaryRest of the World

Salix and Alfa Wassermann expand rifaximin accord


USA-based Salix Pharmaceuticals (Nasdaq: SLXP) and Italy's Alfa Wassermann have entered into an exclusive…

Alfa WassermannGastro-intestinalsLicensingPharmaceuticalRespiratory and PulmonaryrifaximinSalix Pharmaceuticals

Paladin gets certain rights to Immuron’s Travelan in up to C$117 million deal


Melbourne, Australia-based Immuron (ASX: IMC) and Canada’s Paladin Labs (TSX: PLB) have signed a…

Gastro-intestinalsImmuronLicensingPaladin LabsPharmaceuticalRespiratory and PulmonaryTravelan

Anti-inflammatory therapeutics market to grow to $85.9 billion in 2017


The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications.…

Anti-Arthritics/RheumaticsGastro-intestinalsMarkets & MarketingNeurologicalPharmaceuticalRespiratory and Pulmonary

Nycomed to market Almirall’s Kestine in Southeast Asia markets; files for linaclotide in EU


Swiss drug maker Nycomed, currently the subject of a 9.6 billion-euro takeover by Japan’s Takeda…

AlmirallAsia-PacificEuropeGastro-intestinalsLicensinglinaclotideNycomedPharmaceuticalRegulationRespiratory and Pulmonary

Karo Bio and Zydus Cadila extend anti-inflammatory research agreement


Sweden-based Karo Bio AB (STO:KARO) and India’s Zydus Cadila have agreed to extend their research…

Anti-Arthritics/RheumaticsGastro-intestinalsKaro BioPharmaceuticalResearchRespiratory and PulmonaryZydus Cadila

1 to 9 of 15 results

Back to top